Disease Group Leader, GU Medical Oncology @BIDMChealth @DanaFarber_GU, Asst Prof @harvardmed, dad, cyclist, Far Side superfan
Massachusetts, USA
Joined January 2015
- Tweets1.2K
- Following738
- Followers954
- Likes384
David Einstein retweeted
The MSKCC Genitourinary Oncology Service is looking for a motivated, patient-centered, clinical investigator with a focus on urothelial cancer. Join a great team focused on eradicating GU cancers!
msk.wd108.myworkdayjobs.com/…
David Einstein retweeted
Fair points, nicely laid out.
With ADT, my top Q is: Does giving ADT now buy this patient sufficiently lower risk of something worse down the road?
If 6m ADT with MDT only delays need for ADT in the future, that’s not good enough. Needs to ⬇️death or ⬆️treatment-free survival.
David Einstein retweeted
🌟 Past and current @BIDMC_HOFellows presented at #ASCOQLTY26, including work led by @JRusheen implementing a BILH-wide tobacco screening and cessation referral program.
David Einstein retweeted
Updated LUNAR analysis out in @EUplatinum. Now with a median follow-up of 32 months, exploratory analyses confirm the addition of 177Lu-PNT2002 to SBRT improves polymetastatic PFS (6 or more new lesion), castrate disease-free survival, and CT-based PFS (i.e., conventional MFS) authors.elsevier.com/sd/arti…
David Einstein retweeted
We're hiring! The @WilmotCancer GU Medical Oncology program at the @UofR is recruiting genitourinary medical oncologists to join our team.
Why Wilmot?
• A rapidly growing NCI-designated cancer center
• The largest clinical trials program in the region
• Rochester and the Finger Lakes: a region known for an exceptional quality of life
Whether you're an established GU oncologist or finishing fellowship and looking for a place to build your career, we'd love to talk.
Message me directly to learn more, and please share with any colleagues who might be a good fit.
#GUOncology #MedicalOncology #HemOnc #Oncology #Hiring
David Einstein retweeted
Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber
1) Dr. Nazli Dizman @NazliDizman
2) Dr. Brian Russell @brian_russell39
3) Dr. Hamid Emamekhoo @HamidEmamekhoo
4) Pr. Neeraj Agarwal @neerajaiims
They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology.
Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc
We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands.
Welcome to @CityOfBoston and @DanaFarber!
David Einstein retweeted
With befitting fanfare, we bid farewell to these 8 exceptional @BIDMC_HOFellows who have lived, learned, and cared with the integrity, intellect, and generosity of spirit that define our community. We are so proud to be your colleagues and friends! @rushadpatell
David Einstein retweeted
🎉 Congratulations to our outstanding class of outgoing @BIDMC_HOFellows! We are grateful to have mentored you along your professional journeys and so excited for your exciting futures ahead.
With befitting fanfare, we bid farewell to these 8 exceptional @BIDMC_HOFellows who have lived, learned, and cared with the integrity, intellect, and generosity of spirit that define our community. We are so proud to be your colleagues and friends! @rushadpatell
David Einstein retweeted
📢 PALLIATIVE CARE IS SIMPLY GOOD CARE AIMED TO MEET PEOPLE’S NEEDS!
It is part of routine care.
It is NOT mutually exclusive with active treatment.
There is never “nothing we can do” - there is always something we can do to help.
It’s not always “find a new shiny drug.”
#ASCO26
David Einstein retweeted
SENTRY is an IIT, phase II, for localized HR (N0 on PSMA). RT+18m ADT vs RT+6m ADT/ARPI.
RSI MRI and PSMA PET required. Focal boost required if feasible.
MDT alone encouraged for oligomet recurrence.
Primary endpoint: FFS; “failure” of initial Rx plan = salvage ADT or CRPC.
David Einstein retweeted
@DanaFarber and @DanaFarber_GU 's very own @AtishChoudhury presents compelling de-intensification data from A-DREAM/A032101 in mHSPC: 41% of favorable responders remained treatment-free with testosterone recovery 18 months after ADT + ARPI interruption, supporting treatment holidays as a promising strategy in selected pts.
#ASCO26 #ProstateCancer
@OncoAlert @ASCO @OncBrothers
David Einstein retweeted
Congratulations to our incredible GI Medical Oncologist @BrunoBockorny on his work on KMT2C mutation in GI malignancies! @BIDMC_CancerCtr #ASCO2026
David Einstein retweeted
Congrats to @AtishChoudhury and @CaPsurvivorship for their oral presentations today and how we can adapt treatment interruption and cognitive change from treatment for men with advanced prostate cancer. Huge efforts from them and the study teams @ALLIANCE_org
David Einstein retweeted
Congrats @AtishChoudhury 👉Can we safely de-intensify Rx in exceptional responders with mHSPC/ mAPMS #prostatecancer ? #ASCO2026 A-DREAM data👉Rx holiday after ADT + ARPI may be feasible, with 41% remaining treatment-free with testosterone recovery at 18 mos @OncoAlert @urotoday
David Einstein retweeted
📐 HR 0.68 = a 32% relative risk reduction in recurrence at any given moment during follow-up.
That sounds like a large benefit.
But the absolute numbers tell a different story:
BCG alone: 81.6% disease-free at 2 years
BCG + durvalumab: 86.5% disease-free at 2 years
Absolute difference: ~5%
Since BCG already works well, a big relative reduction maps to a modest absolute gain. @MaxKates @UrogerliMD @JoshMeeks
David Einstein retweeted
Ab#5001 @ASCO #ASCO26 by @ChrisSweens1👉 bit.ly/4dnFUvD👉Decipher Prostate Genomic Classifier (DGC) predicts benefit w/ triplet Rx in #prostatecancer👉DGC>0.85 is predictive of benefit from adding docetaxel to ADT+Enza👇@Prof_IanD @OncoAlert @urotoday @PCF_science
David Einstein retweeted
An important study that highlights the complexity of using PSMA PET as an endpoint.
Prognostic significance of PSMA tumor volume varied between patients with low and high volume of disease (*particularly relevant for #PSMA+BCR):
Clink link to article in European Urology. PSMA total tumour volume at 3months predicts overall survival independent of treatment in ENZAp. This raises important questions about how we should be measuring progression on PSMA. @ANZUPtrials @PCF_Science
authors.elsevier.com/a/1mv80…
David Einstein retweeted
What are the outcomes of #LuPSMA in #octagenarians with advanced prostate cancer? Our collaborative experience with @DanaFarber_GU @MayoClinic @VUMChealth led by Daniel Sentana and Avina Rami, published in @JCOOP_ASCO: ascopubs.org/doi/10.1200/OP-…
David Einstein retweeted
LBA1/Plenary #ASCO26: PROTEUS trial
Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC
Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage !
@DanaFarber @DanaFarber_GU @ASCO @OncoAlert
David Einstein retweeted
📣🚨🚨Are we measuring the most meaningful endpoint? A question raised to the RadOnc community by @davidjeinstein
In the era of MDT and intermittent therapies, Treatment-Free Survival (TFS) may better capture real benefit.
Our new editorial in @IJROBP explores why!
